

PRESS RELEASE



Release Date:  
1 June 2024

## **VERIVAS ANNOUNCES THEIR NEW PATENT, THE RAPID VEIN HARVESTER, AN ENTIRELY NEW WAY OF HARVESTING VEINS FOR VASCULAR BYPASS PROCEDURES**

STAMFORD, CONNECTICUT - Verivas Solutions Inc. announces its newly patented medical device, the Rapid Vein Harvester (“RVH”). RVH is an entirely new way of harvesting veins for vascular bypass procedures. RVH is unique in its utilization of percutaneous, endovascular, “over the wire” techniques employing specialized guidewires and catheters for vein inversion and excision to allow rapid, minimally invasive vein harvest.

Coronary arterial bypass and lower extremity bypass procedures are the most common life and limb-saving surgical procedures performed worldwide and commonly utilize veins harvested from the patient’s legs. Over than 400,000 such vascular bypass procedures are performed every year in the U.S. alone. Current techniques for harvesting veins for bypass procedures are either endoscopic or open surgical vein excision. Both techniques are time-consuming to learn and perform. RVH has the advantage of being easy to learn and reduces vein harvest time, significantly reducing operative time, anesthesia duration, and associated risks.

Verivas is an incubator of innovative medical ideas and devices in the medical field.

For more information, please visit the website [verivassolutions.com](http://verivassolutions.com) and contact Stewart Rosenberg.

Contact Information:

Stewart Rosenberg | Co-Founder and CFO  
c. 203.376.7568 | [srosenberg@verivassolutions.com](mailto:srosenberg@verivassolutions.com)

Certain statements in this press release constitute forward-looking statements, are not historical facts, and involve risks and uncertainties that could cause actual results to differ from those expected and projected. Such risks and uncertainties may include, but are not limited to (i) general economic conditions; (ii) conditions specific to the industry; (iii) the company’s ability to develop or acquire new technology or products through licensing, merger or acquisition and to obtain regulatory approval to commercialize diagnostic, therapeutic or preventative products; (iv) the effectiveness and ultimate market acceptance of any such products; (v) limitations on third party reimbursements with respect to any such products; and (vi) competition. The company does not undertake to update or revise any forward-looking statements contained herein whether because of new information, future events or otherwise.

###